We're developing Immubio, an immunisation development and delivery platform based on Nanobiologics, our breakthrough in nanoparticles that combines ultra-diluted, patent-pending antigen called Nantigen and Moleculebase, a framework for specific molecule selection to safely prime targeted mechanisms leading to beneficial physiological outcomes for target diseases. Our platform aims to produce immunisations that are highly effective at modulating the immune response, that provide a high level of safety and are less costly than traditional immunisations.  

With a dedication to achieving high efficacy, affordability and speed to market, we are committed to solving today's greatest challenges while striving to create better solutions for the future.

With a strong focus on technology enabled health, we plan to deliver a future health application as part of Immubio that will enable everyone the opportunity to improve their health over time through targeted immunisations, education and collective learning.

Open Care has plans to develop a digital immunisation certificate for the Immunbio platform that will work with our application.

As part of our commitment to enabling better health outcomes for as many people as possible, we plan to partner with governments to provide secure, real time insights and analytics on the efficacy of our immunisations and state of health across our user base to mitigate the spread of disease.

Our team and scientific board bring together decades of experience and research. We are more committed than ever to pursuing our vision for stronger and healthier communities which has its foundation in continual research and development across our platform and to ensure we are always pushing the boundaries of what is possible.

Our planned trials will be conducted with leading partners globally and will conform to the highest international standards while using the best protocols to gather verifiable and actionable data.